Single-cell analysis of severe COVID-19 patients reveals a monocyte-driven inflammatory storm attenuated by Tocilizumab
ABSTRACT Despite the current devastation of the COVID-19 pandemic, several recent studies have suggested that the immunosuppressive drug Tocilizumab can powerfully treating inflammatory responses that occur in this disease. Here, by employing single-cell analysis of the immune cell composition of severe-stage COVID-19 patients and these same patients in post Tocilizumab-treatment remission, we have identified a monocyte subpopulation specific to severe disease that contributes to inflammatory storms in COVID-19 patients. Although Tocilizumab treatment attenuated the strong inflammatory immune response, we found that immune cells including plasma B cells and CD8+ T cells still exhibited an intense humoral and cell-mediated anti-virus immune response in COVID-19 patients after Tocilizumab treatment. Thus, in addition to providing a rich, very high-resolution data resource about the immune cell distribution at multiple stages of the COVID-19 disease, our work both helps explain Tocilizumab’s powerful therapeutic effects and defines a large number of potential new drug targets related to inflammatory storms..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 01. Dez. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Chuang [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.04.08.029769 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI014896796 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI014896796 | ||
| 003 | DE-627 | ||
| 005 | 20230429095204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200414s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.04.08.029769 |2 doi | |
| 035 | |a (DE-627)XBI014896796 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.04.08.029769 | ||
| 035 | |a (biorXiv)10.1101/2020.04.08.029769 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Guo, Chuang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Single-cell analysis of severe COVID-19 patients reveals a monocyte-driven inflammatory storm attenuated by Tocilizumab |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Despite the current devastation of the COVID-19 pandemic, several recent studies have suggested that the immunosuppressive drug Tocilizumab can powerfully treating inflammatory responses that occur in this disease. Here, by employing single-cell analysis of the immune cell composition of severe-stage COVID-19 patients and these same patients in post Tocilizumab-treatment remission, we have identified a monocyte subpopulation specific to severe disease that contributes to inflammatory storms in COVID-19 patients. Although Tocilizumab treatment attenuated the strong inflammatory immune response, we found that immune cells including plasma B cells and CD8+ T cells still exhibited an intense humoral and cell-mediated anti-virus immune response in COVID-19 patients after Tocilizumab treatment. Thus, in addition to providing a rich, very high-resolution data resource about the immune cell distribution at multiple stages of the COVID-19 disease, our work both helps explain Tocilizumab’s powerful therapeutic effects and defines a large number of potential new drug targets related to inflammatory storms. | ||
| 700 | 1 | |a Li, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaofang |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Pengfei |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Qiaoni |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Liying |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Jingwen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zong, Dandan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yichen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xuyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Binqing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lianxin |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiaoling |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Jianping |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Haiming |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Tengchuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Kun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 01. Dez. |
| 773 | 1 | 8 | |g year:2020 |g day:01 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-020-17834-w |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.04.08.029769 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 01 |c 12 | ||
| 953 | |2 045F |a 570 | ||